REPLIGEN CORP Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
REPLIGEN CORP (RGEN) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $26.54 million as of 2014-06-02, per its 10-K filed 2016-02-25.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2016-02-25
- 2014-06-02: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $26.54M; Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net as first filed $26.54M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net as first filed |
|---|---|---|
| 2014-06-02 | $26.54M 10-K · filed 2016-02-25 | $26.54M 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |